Radioprotection in mice following oral administration of WR-1065/PLGA nanoparticles

References

• Andreassen C N, Grau C, Lindegaard J C. Chemical radioprotection: A critical review of amifostine as a cytoprotector in radiotherapy. Seminars in Radiation Oncology 2003; 13: 62–72
   PubMed Web of Science ®Google Scholar
• Batista C KLP, Mota J MSC, Souza M LP, Leitao B TA, De Souza M HLP, Brito G AC, Cunha F Q, Ribeiro R A. Amifostine and glutathione prevent ifosfamide- and acrolein-induced hemorrhagic cystitis. Cancer Chemotherapy and Pharmacology 2007; 59: 71–77
   PubMed Web of Science ®Google Scholar
• Belkacemi Y, Rat P, Piel G, Christen M O, Touboul E, Warnet J M. Lens epithelial cell protection by aminothiol WR-1065 and anetholedithiolethione from ionizing radiation. International Journal of Cancer 2001; 96(Suppl.)15–26
   PubMedGoogle Scholar
• Ben-Josef E, Han S, Tobi M, Vargas B J, Stamos B, Kelly L, Priggar S, Kaplan I. Intrarectal application of amifostine for the prevention of radiation-induced rectal injury. Seminars in Radiation Oncology 2002; 12: 81–85
   PubMed Web of Science ®Google Scholar
• Beutel J, Schroder C, von Hof K, Rades D, Kosmehl H, Wedel T, Sieg P, Geerling G, Hakim S G. Pharmacological prevention of radiation-induced dry eye-an experimental study in a rabbit model. Graefes Archive for Clinical and Experimental Ophthalmology 2007; 245: 1347–1355
   PubMed Web of Science ®Google Scholar
• Bonner S H, Shaw L M. New dosing regimen for amifostine: A pilot study to compare the relative bioavailability of oral and subcutaneous administration with intravenous infusion. Journal of Clinical Pharmacology 2002; 42: 166–174
   PubMed Web of Science ®Google Scholar
• Cassatt D R, Fazenbaker C A, Bachy C M, Kifle G, McCarthy M P. Amifostine (ETHYOL) protects rats from mucositis resulting from fractionated or hyperfractionated radiation exposure. International Journal of Radiation Oncology, Biology, Physics 2005; 61(3)901–907
   PubMedGoogle Scholar
• Evans H H, Evans T E, Horng M F. Antimutagenecity of WR-1065 in L5178Y cells exposed to accelerated (56) Fe ions. Radiation Research 2002; 158(1)110–114
   PubMedGoogle Scholar
• Fatome M, Courteille F, Laval J D, Roman V. Radioprotective activity of ethylcellulose microspheres containing WR 2721, after oral administration. International Journal of Radiation Biology and Related Studies in Physics, Chemistry, and Medicine 1987; 52: 21–29
   PubMed Web of Science ®Google Scholar
• Ganz T. Paneth cells-guardians of the gut cell. Nature Immunology 2000; 1: 99–100
   PubMedGoogle Scholar
• Geary R S, Swynnerton N F, Timmons S F, Mangold D J. Characterization of ethiofos absorption in the rat small intestine. Biopharmaceutics & Drug Disposition 1991a; 12: 261–274
   PubMedGoogle Scholar
• Geary R S, Swynnerton N F, Timmons S F, Mangold D J. Characterization of WR-1065 absorption in the rat small intestine. Biopharmaceutics & Drug Disposition 1991b; 12: 275–284
   PubMedGoogle Scholar
• Gogu S R, Beckman B S, Rangan S RS, Agrawal K C. A significant increase in therapeutic effect of zidvudine in the presence of vitamin E. Biochemical and Biophysical Research Communications 1989; 165: 401–407
   PubMed Web of Science ®Google Scholar
• Harari Y, Grossie V B, Castro A. Nutritional support for adaptation to radiation-induced suppression of mucosal immunity in the intestine of the rat. Radiation Research 1996; 145: 754–761
   PubMedGoogle Scholar
• Hatoum G F, Nevaldine B, Bhavsar T, Phung Q, Hahn P J. WR-1065, the active form of amifostine, protects HL-60 cells but not peripheral blood mononuclear cells from radiation and etoposide-induced apoptosis. International Journal of Radiation Oncology, Biology, Physics 2004; 59: 844–851
   PubMedGoogle Scholar
• Jin J O, Lehmann J, Taxy J, Huo D, Stokle M, Vogelzang N J, Steinberg G, Stadler W M. Phase II trial of adjuvant gemcitabine plus cisplatin-based chemotherapy in patients with locally advanced bladder cancer. Clinical Genitourinary Cancer 2006; 5: 150–154
   PubMedGoogle Scholar
• Kouvaris J R, Kouloulias V E, Vlahos L J. Amifostine: The first selective-target and broad-spectrum radioprotector. The Oncologist 2007; 12: 738–747
   PubMed Web of Science ®Google Scholar
• Mangold D J, Huelle B K, Miller M A, Geary R S, Sanchez-Barona D OT, Swynnerton N F, Fleckenstein L, Ludden T M. Pharmacokinetics and disposition of WR-1065 in the rhesus monkey. Drug Metabolism and Disposition 1990; 18: 281–287
   PubMedGoogle Scholar
• Mell L K, Malik R, Komaki R, Movsas B, Swann R S, Langer C, Antonadou D, Koukourakis M, Mundt A J. Effect of amifostine on response rates in locally advanced non-small-cell lung cancer patients treated on randomized controlled trials: A meta-analysis. International Journal of Radiation Oncology, Biology, Physics 2007; 68: 111–118
   PubMed Web of Science ®Google Scholar
• Mota J MSC, Soares P MG, Menezes A AJ, Lemos H P, Cunha F Q, Brito G AC, Ribeiro R A, De Souza M HLP. Amifostine (WR-2721) prevents indomethacin-induced gastric damage in rats: Role of non-protein sulfhydryl groups and leukocyte adherence. Digestive Diseases and Sciences 2007; 52: 119–125
   PubMed Web of Science ®Google Scholar
• Pamujula S, Graves R, Kishore V, Mandal T K. Preparation and in vitro characterization of amifostine biodegradable microcapsules. European Journal of Pharmaceutics and Biopharmaceutics 2004; 57: 213–221
   PubMed Web of Science ®Google Scholar
• Pamujula S, Kishore V, Rider B, Fermin C, Graves R, Agrawal K, Mandal T K. Radioprotection in mice following oral delivery of amifostine nanoparticles. International Journal of Radiation Biology 2005; 81: 251–257
   PubMed Web of Science ®Google Scholar
• Praetorius N, Mandal T K. Alternate delivery route for amifostine as a radio-/chemo-protecting agent. Journal of Pharmacy and Pharmacology 2008; 60: 809–815
   PubMed Web of Science ®Google Scholar
• Singh A K, Menard C, Guion P, Simone N L, Smith S, Crouse N S, Godette D J, Cooley-Zgela T, Sciuto L C, Coleman J, Pinto P, Albert P S, Camphausen K, Coleman C N. Intrarectal amifostine suspension may protect against acute proctitis during radiation therapy for prostate cancer: A pilot study. International Journal of Radiation Oncology, Biology, Physics 2006; 65: 1008–1013
   PubMed Web of Science ®Google Scholar
• Srinivasan V, Pendergrass J A, Kumar K S, Landauer M R, Seed T M. Radioprotection, pharmacokinetic and behavioral studies in mouse implanted with biodegradable drug (amifostine) pellets. International Journal of Radiation Biology 2002; 78: 535–543
   PubMed Web of Science ®Google Scholar
• Uma D P, Veena K. Mouse jejunal response to multifraction treatments with gamma radiation and chemicals. Strahlentherapie und Onkologie 1993; 169: 196–201
   PubMedGoogle Scholar
• Weiss J F, Landauer M R, Hogan J B, Gunter-Smith P J, Benson K A, Neta R, Hanson W R. Modification of radiation-induced gastrointestinal and hematopoietic injury in mice by combinations of agents: Effects of indomethacin and caffeine. Advances in Experimental Biology 1997; 400B: 865–872
   PubMed Web of Science ®Google Scholar